Balaji Prasad
Stock Analyst at Barclays
(2.32)
# 1,433
Out of 4,412 analysts
88
Total ratings
41.38%
Success rate
-2.06%
Average return
Main Sectors:
18 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZTS Zoetis | Maintains: Overweight | $260 → $230 | $158.42 | +45.18% | 8 | Apr 23, 2024 | |
| ALVO Alvotech | Maintains: Overweight | $17 → $20 | $14.15 | +41.34% | 3 | Mar 22, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $235 → $230 | $109.46 | +110.12% | 3 | Mar 1, 2024 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $40 → $50 | $32.04 | +56.05% | 2 | Feb 28, 2024 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $18 → $19 | $13.26 | +43.29% | 6 | Feb 27, 2024 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $605 → $655 | $499.30 | +31.18% | 6 | Feb 6, 2024 | |
| TEVA Teva Pharmaceutical | Maintains: Overweight | $15 → $17 | $13.81 | +23.10% | 6 | Feb 5, 2024 | |
| RVNC Revance Therapeutics | Maintains: Overweight | $35 → $10 | $3.40 | +194.12% | 7 | Jan 29, 2024 | |
| RDY Dr. Reddy's Laboratories | Maintains: Overweight | $75 → $80 | $74.55 | +7.31% | 9 | Jan 29, 2024 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $6 → $8 | $5.87 | +36.29% | 3 | Jan 29, 2024 | |
| EOLS Evolus | Upgrades: Overweight | $10 → $16 | $11.43 | +39.98% | 4 | Jan 29, 2024 | |
| PYPD PolyPid | Maintains: Equal-Weight | $2.5 → $10 | $4.75 | +110.42% | 2 | Oct 23, 2023 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $60 → $57 | $26.33 | +116.48% | 3 | Oct 23, 2023 | |
| CHRS Coherus BioSciences | Maintains: Overweight | $8 → $7 | $2.04 | +243.14% | 5 | Oct 23, 2023 | |
| OGN Organon & Co. | Initiates: Overweight | $28 | $18.55 | +50.94% | 1 | Sep 21, 2023 | |
| LGND Ligand Pharmaceuticals | Maintains: Overweight | $120 → $110 | $70.57 | +55.87% | 9 | Jul 25, 2023 | |
| VTRS Viatris | Downgrades: Underweight | $11 | $11.57 | -4.93% | 6 | Jun 23, 2023 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $22 → $17 | $12.73 | +33.54% | 5 | Sep 16, 2022 |
Zoetis
Apr 23, 2024
Maintains: Overweight
Price Target: $260 → $230
Current: $158.42
Upside: +45.18%
Alvotech
Mar 22, 2024
Maintains: Overweight
Price Target: $17 → $20
Current: $14.15
Upside: +41.34%
Jazz Pharmaceuticals
Mar 1, 2024
Maintains: Overweight
Price Target: $235 → $230
Current: $109.46
Upside: +110.12%
Tarsus Pharmaceuticals
Feb 28, 2024
Maintains: Overweight
Price Target: $40 → $50
Current: $32.04
Upside: +56.05%
Elanco Animal Health
Feb 27, 2024
Maintains: Overweight
Price Target: $18 → $19
Current: $13.26
Upside: +43.29%
IDEXX Laboratories
Feb 6, 2024
Maintains: Overweight
Price Target: $605 → $655
Current: $499.30
Upside: +31.18%
Teva Pharmaceutical
Feb 5, 2024
Maintains: Overweight
Price Target: $15 → $17
Current: $13.81
Upside: +23.10%
Revance Therapeutics
Jan 29, 2024
Maintains: Overweight
Price Target: $35 → $10
Current: $3.40
Upside: +194.12%
Dr. Reddy's Laboratories
Jan 29, 2024
Maintains: Overweight
Price Target: $75 → $80
Current: $74.55
Upside: +7.31%
Amneal Pharmaceuticals
Jan 29, 2024
Maintains: Overweight
Price Target: $6 → $8
Current: $5.87
Upside: +36.29%
Evolus
Jan 29, 2024
Upgrades: Overweight
Price Target: $10 → $16
Current: $11.43
Upside: +39.98%
PolyPid
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $4.75
Upside: +110.42%
Pacira BioSciences
Oct 23, 2023
Maintains: Overweight
Price Target: $60 → $57
Current: $26.33
Upside: +116.48%
Coherus BioSciences
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $2.04
Upside: +243.14%
Organon & Co.
Sep 21, 2023
Initiates: Overweight
Price Target: $28
Current: $18.55
Upside: +50.94%
Ligand Pharmaceuticals
Jul 25, 2023
Maintains: Overweight
Price Target: $120 → $110
Current: $70.57
Upside: +55.87%
Viatris
Jun 23, 2023
Downgrades: Underweight
Price Target: $11
Current: $11.57
Upside: -4.93%
Phibro Animal Health
Sep 16, 2022
Maintains: Underweight
Price Target: $22 → $17
Current: $12.73
Upside: +33.54%